Рет қаралды 1,316
Neoadjuvant nivolumab plus chemotherapy is standard therapy for resectable non-small-cell lung cancer. Whether the addition of adjuvant nivolumab may improve outcomes is unclear.
Research findings are summarized in a new Quick Take video.
To see the full article, follow this link: nej.md/3VaMtbX
#oncology #criticalcare #nejm